Welcome to our dedicated page for Ampio Pharma news (Ticker: AMPE), a resource for investors and traders seeking the latest updates and insights on Ampio Pharma stock.
Ampio Pharmaceuticals, Inc. (AMPE) is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory conditions. This dedicated news hub provides investors and industry observers with essential updates on clinical trial progress, regulatory developments, and strategic partnerships.
Our curated collection offers immediate access to official press releases and verified news coverage, enabling stakeholders to track AMPE's research advancements in osteoarthritis treatment and inflammatory diseases. Key updates include phase trial results, FDA correspondence, and collaboration announcements with leading medical institutions.
Regularly updated with primary source materials, this resource serves as a reliable reference for understanding AMPE's scientific approach and business strategy. Users will find chronological documentation of patent filings, peer-reviewed study publications, and financial disclosures.
Bookmark this page to maintain current awareness of Ampio Pharmaceuticals' position in the competitive biotech landscape. Check back frequently updated content to support informed analysis of the company's therapeutic pipeline and market potential.
Ampio Pharmaceuticals (NYSE American: AMPE) announced the completion of enrollment for its Phase I clinical trial of Ampion™ for IV treatment of COVID-19 patients needing supplemental oxygen. Results are expected shortly from the Safety Monitoring Committee. The ongoing Phase III trial for Ampion in treating severe osteoarthritis of the knee (OAK) was paused due to COVID-19 but is set to resume with a proposal to the FDA planned for early Q4 2020. Ampio's product has the potential for significant market exclusivity upon FDA approval.
Ampio Pharmaceuticals (NYSE American: AMPE) announced updates on its COVID-19 clinical trials. The Phase I trial for intravenous Ampion treatment has completed initial safety assessments and is cleared for further patient enrollment. An independent Safety Monitoring Committee reviewed the results, confirming Ampion's safety. Additionally, the FDA requested further safety testing for nebulized Ampion, with preclinical trials showing no toxicity, and the trial protocol is under FDA review. Ampio's lead drug is positioned for 12-year market exclusivity upon FDA approval.
Ampio Pharmaceuticals (NYSE American: AMPE) is advancing its immunology-based therapies with a focus on treating COVID-19. The company has initiated a Phase 1 clinical trial to evaluate the safety and tolerability of its intravenous treatment, Ampion™, for patients requiring supplemental oxygen. This trial aims to assess Ampion's efficacy in addressing the overactive inflammatory response seen in COVID-19 patients. With significant patent protection extending to 2032 and potential FDA market exclusivity, Ampio is positioned to explore promising therapeutic targets amidst the ongoing pandemic.
Ampio Pharmaceuticals (NYSE American: AMPE) announced the publication titled Insights into pediatric multi-system inflammatory syndrome and COVID-19 on July 20, 2020. This study highlights a syndrome resembling Kawasaki Disease in children, which may be treatable with Ampion™. Dr. David Bar-Or emphasizes the potential of Ampion, alone or with IVIG, to address this condition. The company continues its evaluation of Ampion as a viable treatment option. Ampio holds a robust patent portfolio and anticipates 12-year FDA market exclusivity upon approval as a novel biologic.
Ampio Pharmaceuticals (AMPE) has received FDA clearance to initiate human trials for its IV Ampion™ treatment aimed at COVID-19 patients who require supplemental oxygen. The Phase 1 clinical trial will assess Ampion's effectiveness as an immunomodulatory anti-inflammatory agent to combat the inflammatory processes associated with COVID-19. Previous in-vitro studies suggest Ampion may be beneficial in treating acute respiratory distress syndrome (ARDS) and cytokine storms linked to the virus. The product is protected by an extensive patent portfolio and may enjoy FDA market exclusivity upon approval.
FAQ
What is the current stock price of Ampio Pharma (AMPE)?
What is the market cap of Ampio Pharma (AMPE)?
